Can Cassava Sciences Resurrect When Simufilam is Used to Treat Seizures Related to Rare Neurodevelopmental Disorders Instead of Alzheimer’s Disease?
February 28, 2025
0
Cassava Sciences in the NEWS Cassava Sciences, Inc. (SAVA) announced that it entered into an agreement with Yale University for a license to intellectual property rights, including an exclusive license to an issued US method of treatment patent (US 12,186,3071) for simufilam as a potential treatment for seizures related to rare neurodevelopmental disorders including tuberous sclerosis complex (TSC). Simufilam is Cassava . . . This content is …